I was raised in Loveland, Colorado. I earned my Bachelor of Science Degree from the Purdue University School of Science in Molecular Biology with research honors. I conducted undergraduate research to understand why leeches can regenerate their nerve cord but humans cannot regenerate their spinal cord. I then directly entered the PIBS program at the University of Michigan at Ann Arbor and joined the Neuroscience Program. In completing my Ph.D. I earned an F31 fellowsihp from NIH and published several papers on the intracellular protein:protein interactions of the amyloid precursor protein. From there I moved to my first postdoctoral fellowship at Cedar-Sinai Medical Center's Gene Therapeutics Research Inistitute. I was earned an F32 fellowship from NIH for my work characterizing a combination therapy to treat glioma. My second postdoctoral fellowship was at Boston University's Biochemistry Department. There I conducted work to understand the mechanisms of age-related klotho gene expression downregulation. I was earned a K99/R01 NIH award to transition from postdoctoral fellow to tenure-track Faculty. I moved to the University of Alabama at Birmingham taking my first faculty position in the Department of Neurobiology in the School of Medicine. There I taught medical, graduate, and undergraduate courses. I also published papers from the discoveries made in my research lab and mentored undergraduate, post-bac, and Ph.D. students. I earned several small grants and an R56 from NIH. I am currently a member of the Creighton Biology faculty supporting the interdepartmental Neuroscience Program in every academic direction: service, teaching, and research. My lab was awarded its first R15 at Creighton in 2020 where we use mouse models of aging to understand age-related change of the brain. Information about my research, past and present can be found at gdkinglab.com.
Teaching Interests
Neuroscience
Research Focus
I am interested in changes that occur in the brain as a result of the normal aging process. Understanding the breakpoints between normal aging and development of neurodegenerative disease is crucial to developing new therapies to treat and prevent neurodegeneration. My lab website is : gdkinglab.com.
Journal of Molecular Cell Biology Shah/Jiang, A chromatin modulator sustains self-renewal and enables differentiation of postnatal neural stem and progenitor cells. 12, p. 4-16 2020
JCI: Insight Xiao/Quarles, FGF23 expression is stimulated in transgenic -Klotho longevity mouse model 4 2019
Am J Physiol Lung Cell Mol Physiol Barnes/Krick, Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis 217, p. L141-L154 2019
Molecular and Cellular Neuroscience Vo/King, Klotho deficiency affects the spine morphology and network synchronization of neurons. 98, p. 1-11 2019
Eneuro Laszczyk/King, FGF-23 Deficiency Impairs Hippocampal-Dependent Cognitive Function 6 2019
Brain Plasticity Vo/King, Klotho, the Key to Healthy Brain Aging? 3, p. 183-194 2018
European Respiratory Journal Krick/Salathe, Fibroblast growth factor 23 and Klotho contribute to airway inflammation. 52 2018
J Am Soc Nephrol Han/Quarles, Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene. 29, p. 69-80 2018
Neurobiology of Aging Laszczyk/King, Klotho regulates postnatal neurogenesis and protects against age-related spatial memory loss. 59, p. 41-54 2017
Am J Hypertension Liu/Sun, Differential Regulatory Role of Soluble Klothos on Cardiac Fibrogenesis in Hypertension. 29, p. 1140-47 2016
PLoS One Han/Quarles, Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport. 2016
FEBS Lett. Han/Quarles, Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. 590, p. 53-67 2016
PLoS Genetics Watson/Wilson, Motor and Sensory Deficits in the teetering Mice Result from Mutation of the ESCRT Component HGS. 11 2015
Mol Neurodegener Vaden/Wilson, Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction. 10 2015
Monoclon Antib Immunodiagn Immunother Maltare/King, Development and characterization of monoclonal antibodies to detect klotho. 33, p. 420-7 2014
Age Mehi/King, MicroRNA-339 and microRNA-556 regulate Klotho expression in vitro. 36, p. 141-9 2014
J. Biol. Chem. Tucker/Abraham, Biochemical and functional characterization of the klotho-VS polymorphism implicated in aging and disease risk. 2013
Investigative Ophthalmology Visual Science Reish/King, The age-regulating protein klotho is vital to sustain retinal function. 51, p. 6675-85 2013
Brain Res Clinton/King, Expression of klotho mRNA and protein in rat brain parenchyma from early postnatal development into adulthood. 1527, p. 1-14 2013
Age King/Abraham, Promoter methylation and age-related downregulation of Klotho in rhesus monkey. 36, p. 1405-19 2012
Neoplasia Candolfi/Castro, Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. 2012
King/Abraham, Identification of novel small molecules that elevate Klotho expression. 441, p. 453-61 2012
Am J Neurodegener Dis So/Abraham, Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein dimerization. 2012
Molecular Therapy King/Lowenstein, Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. 19, p. 1793-801 2011
Clin Cancer Res Mineharu/Castro, Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design 2011
Current Gene Therapy Castro/Lowenstein, Gene therapy and targeted toxins for glioma. 44, p. 155-80 2011
Clin Cancer Res Muhammad/Castro, Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. 2009
Clin Cancer Res Candolfi/Castro, Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. 2009
J. Virol. King/Castro, High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. 82, p. 4680-4 2008
Molecular Therapy King/Castro, Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. 16, p. 682-90 2008
Neuro-Oncology King/Castro, Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. 10, p. 19-31 2008
Molecular Therapy Barcia/Lowenstein, One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. 2007
J Neurooncol Candolfi/Castro, Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. 2007
J Exp Med Barcia/Lowenstein, In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. 2006
J Immunol Curtin/Castro, Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. 2006
J Virol Xiong/Castro, Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. 2006
Current Gene Therapy King/Castro, Gene therapy and targeted toxins for glioma. 5, p. 535-57 2005
Cancer Research Ali/Castro, Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. 65, p. 7194-204 2005
Molecular Therapy Goverdhana/Castro, Regulatable gene expression systems for gene therapy applications: progress and future challenges. 2005
Curr Top Med Chem Curtin/Castro, Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. 2005
Molecular Therapy Ali/Castro, Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. 2004
J Neurochem King/Turner, X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. 88, p. 971-82 2004
Experimental Neurology King/Turner, Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? 2004
Neuroscience King/Turner, X11alpha modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the YENPTY sequence. 120, p. 143-54 2003